What published research reports on Semax in optic-nerve and eye studies

Published August 26, 2026 · Artemis Labs

Semax — answer capsule: Semax is a seven-amino-acid peptide studied almost entirely in Russia, and a small corner of that work looked at the eye and the optic nerve. Five PubMed-indexed human records name Semax in eye conditions — optic nerve disease, glaucoma-related optic neuropathy, diabetic retinopathy, optic neuropathies of mixed causes, and recovery after retinal detachment surgery. Every one of those studies gave Semax as one part of a combined treatment program, so none of them can separate what Semax did from what the rest of the program did. All were conducted in Russia; no study outside Russia has tested Semax in people for any condition at all. In rats, a Moscow laboratory measured neurotrophin gene activity in retinal tissue and found the change ran in more than one direction rather than simply upward.

Key findings

• The one eye study carrying a clinical-trial publication type is a 2000 report in the Russian journal Vestnik Oftalmologii, titled [Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease]. It had a control group, but Semax was added on top of existing care — the authors’ own words are in parallel with basic neurotrophic and antiinflammatory therapy (PMID 10741256).
• A 2001 glaucoma report from the same Russian journal compared A complex of neuroprotective therapy, including a new Russian neuropeptide semax against traditional neuroprotective treatment. The comparison was program versus program, not Semax versus no Semax, and the abstract gives no patient count (PMID 11569188).
• Three later Russian eye records — from the Krasnov Research Institute of Eye Diseases in Moscow, the Research Institute of Eye Diseases in Moscow, and a 2013 diabetic retinopathy report — all placed Semax inside combined physiotherapy programs, which again makes the peptide’s own contribution impossible to read off (PMIDs 42366656, 36083821, 24437205).
• In rats, neurotrophin gene expression in retinal tissue moved both ways after Semax. The authors describe the pattern with their own word, multidirectional, and report a decrease in retina at 20 minutes (PMID 19662538).

What did the human optic-nerve study report?

The oldest and most direct human record in this area is PMID 10741256, published in 2000 in Vestnik Oftalmologii, a Russian-language Russian ophthalmology journal. PubMed classifies it as a Clinical Trial and a Controlled Clinical Trial. The PubMed record supplies no institutional affiliation for it, so the country comes from the journal, the language, and the title itself, which calls Semax a new Russian drug. Patients were divided into three groups, and the third group served as the control. The abstract gives no patient count.

What the authors reported, in their own words: Addition of semax to therapeutic complex in patients with diseases of the optic nerve had a favorable impact on the intensity and rate of recovery and improved the visual functions. The specific measures they listed were improvement of visual acuity, extension of the total visual field, increase in the electric sensitivity and conductivity of the optic nerve, and improvement of color vision.

One phrase in that abstract governs how the whole result should be read. Semax was given in parallel with basic neurotrophic and antiinflammatory therapy. Every patient was already receiving other treatment. That design can suggest an add-on effect; it cannot show what Semax does by itself.

What about glaucoma and the later eye studies?

PMID 11569188, from 2001 and also in Vestnik Oftalmologii, looked at glaucomatous optic neuropathy — damage to the optic nerve in glaucoma patients — in people whose eye pressure had already been brought to normal. The authors wrote that A complex of neuroprotective therapy, including a new Russian neuropeptide semax, was used and that Electrophysiological and computer methods of examination demonstrated the advantages of new therapy over traditional neuroprotective treatment for glaucoma. The abstract then adds that the efficiency is due to Semax’s neuroprotective and neurotrophic effects. That last line is the authors’ interpretation, not something the study measured, and the study reports no patient count.

Three more recent Russian records place Semax in the same kind of package. A 2026 report from the Krasnov Research Institute of Eye Diseases in Moscow examined a combined physiotherapeutic approach after surgery for retinal detachment (PMID 42366656). A 2022 report from the Research Institute of Eye Diseases in Moscow covered complex physiotherapeutic neurostimulation in optic neuropathies of various causes (PMID 36083821). A 2013 report on rehabilitative treatment in diabetic retinopathy combined pre-formed physical factors with neuroprotective therapy; PubMed supplies no affiliation for it, and the country again comes from the Russian journal and Russian language (PMID 24437205). In all three, Semax is one ingredient among several.

What did animal work find in retinal tissue?

One Russian rat study measured the activity of two neurotrophin genes — NGF and BDNF, genes for proteins that support nerve cells — in the hippocampus, frontal cortex, and retina after Semax. The result is not a clean increase, and it belongs on this page precisely because retina was one of the tissues measured. Verbatim: The expression of both neurotrophin genes was decreased in rat hippocampus and retina 20 min after Semax administration and was increased in the frontal cortex. The authors’ own summary word for the pattern is multidirectional. They also report that The expression levels of NGF remained practically constant in the retina at the initial stage, whereas the expression levels of BDNF were significantly increased 90 min after Semax administration (PMID 19662538). In retinal tissue, then, the direction of change depended on which gene was measured and when. Anyone summarizing this as “Semax raises BDNF” is reading one line out of a paper that reports both directions. Our companion page on Semax neuroprotection research covers the same finding in the brain regions.

A separate Russian rat experiment used a radioactively labelled version of the peptide and reported that the peptide actively penetrates into the brain and eyes of experimental animals (PMID 15678666). That is a distribution finding in animals — it says where a labelled molecule was detected, not that anything therapeutic happened in the eye.

What the research does not show

No Semax study in people has been conducted outside Russia, in this eye lane or any other. There are no meta-analyses of Semax indexed in PubMed, no systematic reviews, no double-blind studies, and no independent replication of any Russian result in either direction. A 2026 United States review of neuroactive peptides states plainly that there is a current lack of clinical trials (PMID 41490200), and a 2026 review that searched regulatory databases through January 2026 lists Semax among Non-approved peptides (PMID 42021992).

Within the eye studies specifically, three limits stand out. First, not one of the five human records isolates Semax — every design layers it onto other therapy, so no reported visual change can be assigned to the peptide alone. Second, two of the human eye records give no patient count at all in their abstracts, and none of the five describes randomization or blinding. Third, the animal retina finding cuts against a simple story: gene expression went down in retina at 20 minutes before BDNF went up at 90 minutes (PMID 19662538).

One more fact from the wider human record belongs here. The single study PubMed tags as a Randomized Controlled Trial was in motor neuron disease, not eye disease, and it was negative on its primary endpoint — Semax (1% solution) does not influence either the course of CPD or the dynamics of clinical estimates (PMID 18379501). We cover that record in more detail on our page about Semax human trials.

Frequently asked questions

How many human eye studies of Semax exist in PubMed?

We hand-checked five: PMIDs 10741256, 11569188, 42366656, 36083821, and 24437205. We publish that number only because it comes from a named list you can check, not from a database hit count.

Was any of this work done outside Russia?

No. Both older eye reports are Russian-language papers in a Russian ophthalmology journal, and the two institutions named in the newer records are the Krasnov Research Institute of Eye Diseases and the Research Institute of Eye Diseases, both in Moscow.

Did any study show Semax working on its own in the eye?

No. Every human eye record describes Semax as part of a combined program alongside other therapy, and the 2001 glaucoma report compares one program against another rather than Semax against a control.

Does the rat retina finding support an eye benefit?

It does not settle the question either way. It is a gene-expression measurement in rat tissue, and the authors report the change as multidirectional, including a decrease in retina at 20 minutes.

References

1. [Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease]. Vestn Oftalmol, 2000. PMID 10741256.
2. [Semax in the treatment of glaucomatous optic neuropathy in patients with normalized ophthalmic tone]. Vestn Oftalmol, 2001. PMID 11569188.
3. [Effect of a combined physiotherapeutic approach on changes in functional parameters after endovitreal surgery of rhegmatogenous retinal detachment with a favorable anatomical outcome]. Vestn Oftalmol, 2026. Krasnov Research Institute of Eye Diseases, Moscow, Russia. PMID 42366656.
4. [Results of the application of complex physiotherapeutic neurostimulation in optical neuropathies of various genesis]. Vopr Kurortol Fizioter Lech Fiz Kult, 2022. Research Institute of Eye Diseases, Moscow, Russia. PMID 36083821.
5. [The results of the application of the pre-formed physical factors and neuroprotective therapy for the rehabilitative treatment of the patients with diabetic retinopathy]. Vopr Kurortol Fizioter Lech Fiz Kult, 2013. PMID 24437205.
6. Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. J Mol Neurosci, 2010. PMID 19662538 · DOI 10.1007/s12031-009-9270-z.
7. Vestn Oftalmol, 2004 — rat distribution study using tritium-labelled Semax. PMID 15678666.
8. [The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with semax]. Zh Nevrol Psikhiatr Im S S Korsakova, 2007. PMID 18379501.
9. Review, 2026. PMID 41490200 · DOI 10.5435/JAAOSGlobal-D-25-00236.
10. Review, 2026. PMID 42021992 · DOI 10.3389/fragi.2026.1790247.

Methodology: this page draws only on PubMed records retrieved and transcribed by hand for the Artemis Labs Semax citation review, with identity data verified against PubChem. Last verified August 26, 2026.

All compounds sold by Artemis Labs are for laboratory research use only. Nothing on this page is medical advice, and no statement has been evaluated by the FDA.